Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Exact Sciences Corporation (EXAS)

12.84 Up 0.40(3.22%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Exact Sciences Corporation
441 Charmany Drive
Madison, WI 53719
United States - Map
Phone: 608-284-5700
Fax: 608-284-5701

Index Membership:N/A
Full Time Employees:102

Business Summary 

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company’s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Exact Sciences Corporation

Corporate Governance 
Exact Sciences Corporation’s ISS Governance QuickScore as of Apr 1, 2014 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 10; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Kevin T. Conroy , 48
Chairman of The Board, Chief Exec. Officer and Pres
Mr. Maneesh K. Arora , 45
Chief Operating Officer
Dr. Graham P. Lidgard Ph.D., 65
Chief Science Officer and Sr. VP
Mr. Stanley N. Lapidus , 63
Mr. William J. Megan ,
Principal Financial Officer and Sr. VP of Fin.
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders